About AST

Transplant News

February, 2013

February 18, 2013
Yesterday, Congressional leaders introduced legislation to end the research ban on organ donation from HIV-Positive donors to HIV-Positive transplant recipients. The HIV Organ Policy Equity (HOPE) Act would create a potential path for HIV-positive organs to be donated to HIV-positive patients, thus potentially saving the lives of transplant patients languishing on waiting lists. Congresswoman Lois Capps (D-CA) and Senators Barbara Boxer (D-CA), Tom Coburn (R-OK), Tammy Baldwin (D-WI), and Rand Paul (R-KY) introduced the legislation, which charges the Department of Health and Human Services (... Read More...
February 18, 2013
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on positive outcomes from largest liver transplant study ever, comparing Zortress plus reduced-exposure tacrolimus to standard tacrolimus Under trade name Certican®, the drug was approved by European Health Authorities for use in adult liver transplant patients in the fourth... Read More...
February 18, 2013
AST support's the candidacy and application of Dr. Jimmy A. Light for Director of the HRSA Division of Transplantation (DoT). Read the letter from AST President, Dr. Roslyn Mannon.
February 15, 2013
Registry analysis: Inferior early posttransplant outcomes for recipients of right versus left deceased donor kidneys Source: American Journal of Transplantation (subscription required) Anatomical differences between right and left kidneys could influence transplant outcome. Receipt of a right kidney is a risk factor for inferior outcomes in the first year after transplantation. A higher incidence of surgical complications suggests the shorter right renal vein may be contributory. The higher susceptibility of right kidneys to injury should be considered in organ allocation.... Read More...
February 14, 2013
Last night, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act was reintroduced in the US Senate with the bi-partisan support of Senators Richard Durbin (D-IL) and Thad Cochran (R-Miss). This legislation (S.323), which AST has been fighting to pass for years, will finally eliminate the current arbitrary 36-month limit on immunosuppressive drug coverage imposed on Medicare end stage renal disease (ESRD) beneficiaries. Click here to read the press release from Senator Durbin's office with a... Read More...
February 08, 2013
Regional variability in liver waiting list removals causes false ascertainment of waiting list deaths Source: American Journal of Transplantation Authors examine alternative ways of assuring complete documentation of deaths on the Organ Procurement and Transplantation Network (OPTN) Liver Transplant Waiting List and report that the most accurate way is to add to OPTN-reported deaths on the list of all deaths reported in the Social Security Administration Death Master File that occurred within 90 days of a patient's being dropped from the list.... Read More...
February 02, 2013
Iraq vet undergoes successful double-arm transplant Source: CNN A U.S. Army infantryman who lost all four limbs in a 2009 roadside explosion in Iraq has undergone radical transplant surgery that may help him regain use of his arms. In December, the 26-year-old infantryman had successful surgery — a rare double arm transplant — at Johns Hopkins Hospital in Baltimore. Read more.  Blockade of p-selectin sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro, in vivo Source: American Journal of... Read More...
February 02, 2013
There is still time to register for the first annual Cutting Edge of Transplantation (CEOT) meeting this Feb. 14-16 in Scottsdale, Ariz. The full program is available online, including rapid-fire abstract presentations and speed roundtable discussions with subject-matter experts. 
February 02, 2013
If you have not yet remitted payment for your 2013 membership dues, please do so immediately to ensure that you continue to receive all of the benefits of membership with the AST, including discounted meeting registration. Your dues must be paid no later than April 1, 2013 in order to be eligible for member-discounted registration rates to the American Transplant Congress in Seattle. Renewing your membership is easy. Simply log in to the AST website and click on "Renew My Membership" to pay your dues online. A confirmation email will be sent to you... Read More...

January, 2013

January 28, 2013
Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab Source: American Journal of Transplantation (subscription required) Steroid-resistant renal allograft rejections are commonly treated with rabbit antithymocyte globulin (RATG), but alemtuzumab could be an effective, safe and more convenient alternative. Adult patients with steroid-resistant renal allograft rejection treated with alemtuzumab (15–30 mg s.c. on two subsequent days) from 2008 to 2012 were compared to patients treated with RATG.... Read More...

Pages